Posted by Michael Wonder on 17 Jun 2020
Identifying the risks of unproven regenerative medicine therapies
17 June 2020 - In the middle of the coronavirus disease 2019 public health response, many priorities are currently competing for the attention of the US FDA.
Some of these are directly related to the pandemic, but others have been challenging issues for years.
Over the past several years, hundreds of clinics across the US have been offering unproven regenerative medicine therapies to patients for the treatment of conditions ranging from ageing to arthritis to autism.
